After liver transplantation for Budd–Chiari in patients with persistent high-risk thrombophilia (e.g., MPN/APS/PNH) and prior splanchnic thrombosis extension, what is your standard long-term anticoagulation strategy and what objective findings prompt you to intensify or de-escalate it?

Patients with a cause of thrombophilia that is not correctable by liver transplantation should remain anticoagulated post-transplant and need to work closely with the hematologist for follow-up and choice of agents, depending on the disorder. These recommendations apply to JAK2 V617F, antiphospholip...